FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity data.
Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity data.
What's Your Reaction?
